Categories: Mental health

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk

Background

Attention-deficit and hyperactivity disorder (ADHD) is frequently diagnosed in patients with substance use disorders (SUDs), including opioids. There remains concern about the safety and efficacy of prescription amphetamines (PAs) and their impact on effectiveness of opioid use disorder (OUD) treatment with buprenorphine.


Objectives

To assess the effect of PAs on OUD buprenorphine treatment retention and/or SUD-related emergency admission or drug-related poisonings.


Methods

We used a retrospective cohort design with a secondary analysis of data from Merative MarketScan Commercial and Multi-State Medicaid Databases from 1 January 2006 to 31 December 2016. Individuals included were aged 12–64 years, had an OUD diagnosis and were prescribed buprenorphine. Our analysis used multivariable Cox regression to evaluate the relationship between PA receipt and time to buprenorphine discontinuation. The second part focused on subsamples of buprenorphine initiators who had either (1) any SUD-related emergency admissions or (2) drug-related poisoning. These outcomes were modelled as a function of PA exposure using conditional logistic regression models as part of a within-person, case-crossover design.


Findings

Our sample had 90 269 patients with OUD (mean age 34.2 years (SD=11.3)) who initiated buprenorphine. Being prescribed a PA was associated with improved buprenorphine retention among individuals both with (adjusted HR (aHR) 0.91 (95% CI 0.86 to 0.97)) and without a concurrent psychostimulant use disorder (PSUD) (aHR 0.92 (95% CI 0.90 to 0.93)).


Conclusions

PA use was associated with improved buprenorphine retention in people with OUD with and without co-occurring PSUD. The risks of acute SUD-related events and drug-related poisonings associated with PA use did not differ when comparing PA-using days with days without PA use.


Clinical implications

Patients with OUD on buprenorphine should receive treatment with a PA when indicated.

prince

Share
Published by
prince

Recent Posts

Best Air Purifiers in the UK for Managing Asthma

I’ve been toying with the idea of getting an air purifier for my home for…

1 week ago

Minimally important change on the Columbia Impairment Scale and Strengths and Difficulties Questionnaire in youths seeking mental healthcare

Background Evidence-based mental health requires patient-relevant outcome data, but many indicators lack clinical meaning and…

1 week ago

Multigenerational family coaggregation study of obsessive-compulsive disorder and cardiometabolic disorders

Background Obsessive-compulsive disorder (OCD) is associated with an increased risk of morbidity and mortality due…

2 weeks ago

Comparing apples and oranges in youth depression treatments? A quantitative critique of the evidence base and guidelines

Objectives Should a young person receive psychotherapy or medication for their depression and on what…

2 weeks ago